Cite

    Strober, B. et al. (2018). No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis. British journal of dermatology. pp. e105-e107. [Online].